RT Journal Article SR Electronic T1 Immunogenicity of BNT162b2 COVID-19 vaccine in New Zealand adults JF medRxiv FD Cold Spring Harbor Laboratory Press SP 2022.04.05.22273480 DO 10.1101/2022.04.05.22273480 A1 Frances H. Priddy A1 Michael Williams A1 Simon Carson A1 Brittany Lavender A1 Julia Mathieson A1 Chris Frampton A1 Nicole J. Moreland A1 Reuben McGregor A1 Georgia Williams A1 Maia Brewerton A1 Katie Gell A1 James Ussher A1 Graham Le Gros YR 2022 UL http://medrxiv.org/content/early/2022/04/06/2022.04.05.22273480.abstract AB Background There is very little known about SARS-CoV-2 vaccine immune responses in New Zealand populations at greatest risk for serious COVID-19 disease.Methods This prospective cohort study assessed immunogenicity in BNT162b2 mRNA vaccine recipients in New Zealand without previous COVID-19, with enrichment for Māori, Pacific peoples, older adults ≥ 65 years of age, and those with co-morbidities. Serum samples were analysed at baseline and 28 days after second dose for presence of quantitative anti-S IgG by chemiluminescent microparticle immunoassay and for neutralizing capacity against Wuhan, Beta, Delta, and Omicron BA.1 strains using a surrogate viral neutralisation assay.Results 285 adults with median age of 52 years were included. 55% were female, 30% were Māori, 28% were Pacific peoples, and 26% were ≥65 years of age. Obesity, cardiac and pulmonary disease and diabetes were more common than in the general population. All participants received 2 doses of BNT162b2 vaccine. At 28 days after second vaccination, 99.6% seroconverted to the vaccine, and anti-S IgG and neutralising antibody levels were high across gender and ethnic groups. IgG and neutralising responses declined with age. Lower responses were associated with age ≥75 and diabetes, but not BMI. The ability to neutralise the Omicron BA.1 variant in vitro was severely diminished but maintained against other variants of concern.Conclusions Vaccine antibody responses to BNT162b2 were generally robust and consistent with international data in this COVID-19 naïve cohort with representation of key populations at risk for COVID-19 morbidity. Subsequent data on response to boosters, durability of responses and cellular immune responses should be assessed with attention to elderly adults and diabetics.Competing Interest StatementFP reports honorarium from Janssen. The authors declare no other potential conflicts of interest.Funding StatementThe study was funded by New Zealand Ministry of Business, Innovation and Employment under a Strategic Science Investment Fund Programmes Investment contract number: MALA2001 and by New Zealand Ministry of Health.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The New Zealand Ministry of Health COVID-19 Emergency Response Health and Disability Ethics Committee (21/NTB/117). gave ethical approval for this work.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors.